The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Organ response data from the SWOG S1702 trial of isatuximab in relapsed AL amyloidosis
Terri Parker, MD, Yale University School of Medicine, New Haven, CT, briefly outlines the updated results of the Phase II SWOG S1702 trial (NCT03499808), a study evaluating the efficacy of isatuximab in patients with relapsed/refractory (R/R) light chain (AL) amyloidosis. Dr Parker discusses the organ response data, highlighting that the agent elicited cardiac, renal, gastrointestinal, and liver responses in a significant proportion of patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
I’d be delighted to. So S1702 was a Phase II trial looking at isatuximab, which is a CD38 monoclonal antibody in relapsed or refractory AL or light chain amyloidosis. So all patients received isatuximab at a standard dose, so 10 mg per kg IV given on days 1, 8, 15, and 22 for cycle one, and then days one and 15 for cycles two through 24. And so the primary objective of the trial was the overall hematological response rate...
I’d be delighted to. So S1702 was a Phase II trial looking at isatuximab, which is a CD38 monoclonal antibody in relapsed or refractory AL or light chain amyloidosis. So all patients received isatuximab at a standard dose, so 10 mg per kg IV given on days 1, 8, 15, and 22 for cycle one, and then days one and 15 for cycles two through 24. And so the primary objective of the trial was the overall hematological response rate. And that was shown to be 77% in the clinical trial. And the updated data that we presented here at the American Society of Hematology Annual Meeting in 2024 was that of the organ response data. And so what we showed with the organ response data is that cardiac response was 56%, renal response 50% and 100% of the patients who had gastrointestinal and or liver involvement responded, although that was a very small n of 3 patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
